Gelesis Holdings Share Holder Equity 2021-2022 | GLS

Gelesis Holdings share holder equity from 2021 to 2022. Share holder equity can be defined as the sum of preferred and common equity items
Gelesis Holdings Annual Share Holder Equity
(Millions of US $)
2021 $-54
2020 $-41
2019 $
Gelesis Holdings Quarterly Share Holder Equity
(Millions of US $)
2022-06-30 $5
2022-03-31 $10
2021-12-31 $-330
2021-09-30 $-44
2021-06-30 $5
2021-03-31 $5
2020-12-31
2020-09-30 $5
2020-06-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.081B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.984B 9.16
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.873B 0.00
QIAGEN (QGEN) Netherlands $9.383B 15.71
Ginkgo Bioworks Holdings (DNA) United States $4.998B 0.00
Arcus Biosciences (RCUS) United States $1.819B 35.51
Myovant Sciences (MYOV) United Kingdom $1.614B 0.00
Emergent Biosolutions (EBS) United States $1.040B 6.03
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.305B 0.00
Enzo Biochem (ENZ) United States $0.105B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00